Glycine transporter type 1 occupancy by bitopertin

A positron emission tomography study in healthy volunteers

Meret Martin-Facklam, Flavia Pizzagalli, Yun Zhou, Susanne Ostrowitzki, Vanessa Raymont, James R Brasic, Nikhat Parkar, Daniel Umbricht, Robert F Dannals, Ron Goldwater, Dean Foster Wong

Research output: Contribution to journalArticle

Abstract

Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing glutamate neurotransmission by enhancing NMDA receptor transmission is to increase glycine availability by inhibiting the glycine transporter type 1 (GlyT1). This study investigated the relationship between the plasma concentration of the glycine reuptake inhibitor bitopertin (RG1678) and brain GlyT1 occupancy. Healthy male volunteers received up to 175 mg bitopertin once daily, for 10-12 days. Three positron emission tomography scans, preceded by a single intravenous infusion of ∼30 mCi [ 11 C]RO5013853, were performed: at baseline, on the last day of bitopertin treatment, and 2 days after drug discontinuation. Eighteen subjects were enrolled. At baseline, regional volume of distribution (V T) values were highest in the pons, thalamus, and cerebellum (1.7-2.7 ml/cm 3) and lowest in cortical areas (∼0.8 ml/cm 3). V T values were reduced to a homogeneous level following administration of 175 mg bitopertin. Occupancy values derived by a two-tissue five-parameter (2T5P) model, a simplified reference tissue model (SRTM), and a pseudoreference tissue model (PRTM) were overall comparable. At steady state, the relationship between bitopertin plasma concentration and GlyT1 occupancy derived by the 2T5P model, SRTM, and PRTM exhibited an EC 50 of ∼190, ∼200, and ∼130 ng/ml, respectively. E max was ∼92% independently of the model used. Bitopertin plasma concentration was a reliable predictor of occupancy because the concentration-occupancy relationship was superimposable at steady state and 2 days after drug discontinuation. These data allow understanding of the concentration-occupancy-efficacy relationship of bitopertin and support dose selection of future molecules.

Original languageEnglish (US)
Pages (from-to)504-512
Number of pages9
JournalNeuropsychopharmacology
Volume38
Issue number3
DOIs
StatePublished - Feb 2013

Fingerprint

Glycine Plasma Membrane Transport Proteins
Positron-Emission Tomography
Healthy Volunteers
N-Methyl-D-Aspartate Receptors
Glycine
Pons
(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone
Thalamus
Intravenous Infusions
Synaptic Transmission
Pharmaceutical Preparations
Cerebellum
Glutamic Acid
Schizophrenia

Keywords

  • bitopertin
  • glycine reuptake inhibitor
  • glycine transporter 1
  • N-methyl-D-aspartate
  • Receptors
  • RG1678
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Glycine transporter type 1 occupancy by bitopertin : A positron emission tomography study in healthy volunteers. / Martin-Facklam, Meret; Pizzagalli, Flavia; Zhou, Yun; Ostrowitzki, Susanne; Raymont, Vanessa; Brasic, James R; Parkar, Nikhat; Umbricht, Daniel; Dannals, Robert F; Goldwater, Ron; Wong, Dean Foster.

In: Neuropsychopharmacology, Vol. 38, No. 3, 02.2013, p. 504-512.

Research output: Contribution to journalArticle

Martin-Facklam, M, Pizzagalli, F, Zhou, Y, Ostrowitzki, S, Raymont, V, Brasic, JR, Parkar, N, Umbricht, D, Dannals, RF, Goldwater, R & Wong, DF 2013, 'Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers', Neuropsychopharmacology, vol. 38, no. 3, pp. 504-512. https://doi.org/10.1038/npp.2012.212
Martin-Facklam, Meret ; Pizzagalli, Flavia ; Zhou, Yun ; Ostrowitzki, Susanne ; Raymont, Vanessa ; Brasic, James R ; Parkar, Nikhat ; Umbricht, Daniel ; Dannals, Robert F ; Goldwater, Ron ; Wong, Dean Foster. / Glycine transporter type 1 occupancy by bitopertin : A positron emission tomography study in healthy volunteers. In: Neuropsychopharmacology. 2013 ; Vol. 38, No. 3. pp. 504-512.
@article{6fcbca1e2752470aa6926427c986a16f,
title = "Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers",
abstract = "Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing glutamate neurotransmission by enhancing NMDA receptor transmission is to increase glycine availability by inhibiting the glycine transporter type 1 (GlyT1). This study investigated the relationship between the plasma concentration of the glycine reuptake inhibitor bitopertin (RG1678) and brain GlyT1 occupancy. Healthy male volunteers received up to 175 mg bitopertin once daily, for 10-12 days. Three positron emission tomography scans, preceded by a single intravenous infusion of ∼30 mCi [ 11 C]RO5013853, were performed: at baseline, on the last day of bitopertin treatment, and 2 days after drug discontinuation. Eighteen subjects were enrolled. At baseline, regional volume of distribution (V T) values were highest in the pons, thalamus, and cerebellum (1.7-2.7 ml/cm 3) and lowest in cortical areas (∼0.8 ml/cm 3). V T values were reduced to a homogeneous level following administration of 175 mg bitopertin. Occupancy values derived by a two-tissue five-parameter (2T5P) model, a simplified reference tissue model (SRTM), and a pseudoreference tissue model (PRTM) were overall comparable. At steady state, the relationship between bitopertin plasma concentration and GlyT1 occupancy derived by the 2T5P model, SRTM, and PRTM exhibited an EC 50 of ∼190, ∼200, and ∼130 ng/ml, respectively. E max was ∼92{\%} independently of the model used. Bitopertin plasma concentration was a reliable predictor of occupancy because the concentration-occupancy relationship was superimposable at steady state and 2 days after drug discontinuation. These data allow understanding of the concentration-occupancy-efficacy relationship of bitopertin and support dose selection of future molecules.",
keywords = "bitopertin, glycine reuptake inhibitor, glycine transporter 1, N-methyl-D-aspartate, Receptors, RG1678, schizophrenia",
author = "Meret Martin-Facklam and Flavia Pizzagalli and Yun Zhou and Susanne Ostrowitzki and Vanessa Raymont and Brasic, {James R} and Nikhat Parkar and Daniel Umbricht and Dannals, {Robert F} and Ron Goldwater and Wong, {Dean Foster}",
year = "2013",
month = "2",
doi = "10.1038/npp.2012.212",
language = "English (US)",
volume = "38",
pages = "504--512",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Glycine transporter type 1 occupancy by bitopertin

T2 - A positron emission tomography study in healthy volunteers

AU - Martin-Facklam, Meret

AU - Pizzagalli, Flavia

AU - Zhou, Yun

AU - Ostrowitzki, Susanne

AU - Raymont, Vanessa

AU - Brasic, James R

AU - Parkar, Nikhat

AU - Umbricht, Daniel

AU - Dannals, Robert F

AU - Goldwater, Ron

AU - Wong, Dean Foster

PY - 2013/2

Y1 - 2013/2

N2 - Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing glutamate neurotransmission by enhancing NMDA receptor transmission is to increase glycine availability by inhibiting the glycine transporter type 1 (GlyT1). This study investigated the relationship between the plasma concentration of the glycine reuptake inhibitor bitopertin (RG1678) and brain GlyT1 occupancy. Healthy male volunteers received up to 175 mg bitopertin once daily, for 10-12 days. Three positron emission tomography scans, preceded by a single intravenous infusion of ∼30 mCi [ 11 C]RO5013853, were performed: at baseline, on the last day of bitopertin treatment, and 2 days after drug discontinuation. Eighteen subjects were enrolled. At baseline, regional volume of distribution (V T) values were highest in the pons, thalamus, and cerebellum (1.7-2.7 ml/cm 3) and lowest in cortical areas (∼0.8 ml/cm 3). V T values were reduced to a homogeneous level following administration of 175 mg bitopertin. Occupancy values derived by a two-tissue five-parameter (2T5P) model, a simplified reference tissue model (SRTM), and a pseudoreference tissue model (PRTM) were overall comparable. At steady state, the relationship between bitopertin plasma concentration and GlyT1 occupancy derived by the 2T5P model, SRTM, and PRTM exhibited an EC 50 of ∼190, ∼200, and ∼130 ng/ml, respectively. E max was ∼92% independently of the model used. Bitopertin plasma concentration was a reliable predictor of occupancy because the concentration-occupancy relationship was superimposable at steady state and 2 days after drug discontinuation. These data allow understanding of the concentration-occupancy-efficacy relationship of bitopertin and support dose selection of future molecules.

AB - Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing glutamate neurotransmission by enhancing NMDA receptor transmission is to increase glycine availability by inhibiting the glycine transporter type 1 (GlyT1). This study investigated the relationship between the plasma concentration of the glycine reuptake inhibitor bitopertin (RG1678) and brain GlyT1 occupancy. Healthy male volunteers received up to 175 mg bitopertin once daily, for 10-12 days. Three positron emission tomography scans, preceded by a single intravenous infusion of ∼30 mCi [ 11 C]RO5013853, were performed: at baseline, on the last day of bitopertin treatment, and 2 days after drug discontinuation. Eighteen subjects were enrolled. At baseline, regional volume of distribution (V T) values were highest in the pons, thalamus, and cerebellum (1.7-2.7 ml/cm 3) and lowest in cortical areas (∼0.8 ml/cm 3). V T values were reduced to a homogeneous level following administration of 175 mg bitopertin. Occupancy values derived by a two-tissue five-parameter (2T5P) model, a simplified reference tissue model (SRTM), and a pseudoreference tissue model (PRTM) were overall comparable. At steady state, the relationship between bitopertin plasma concentration and GlyT1 occupancy derived by the 2T5P model, SRTM, and PRTM exhibited an EC 50 of ∼190, ∼200, and ∼130 ng/ml, respectively. E max was ∼92% independently of the model used. Bitopertin plasma concentration was a reliable predictor of occupancy because the concentration-occupancy relationship was superimposable at steady state and 2 days after drug discontinuation. These data allow understanding of the concentration-occupancy-efficacy relationship of bitopertin and support dose selection of future molecules.

KW - bitopertin

KW - glycine reuptake inhibitor

KW - glycine transporter 1

KW - N-methyl-D-aspartate

KW - Receptors

KW - RG1678

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84872495665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872495665&partnerID=8YFLogxK

U2 - 10.1038/npp.2012.212

DO - 10.1038/npp.2012.212

M3 - Article

VL - 38

SP - 504

EP - 512

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -